Enliven Therapeutics (ELVN) vs Precigen (PGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Precigen (PGEN) has outperformed Enliven Therapeutics (ELVN) over the past year, gaining 144.8% versus a gain of 92.5%. Over five years, ELVN leads with a +179.9% price change compared with +68.0% for PGEN. Enliven Therapeutics is the larger company by market cap ($3.00 billion vs $2.80 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELVN | PGEN |
|---|---|---|
| Share price | $40.98 | $7.81 |
| Market cap | $3.00B | $2.80B |
| 1-day change | +0.86% | +2.76% |
| YTD return | +166.10% | +86.84% |
| 1-year return | +92.48% | +144.83% |
| 5-year return | +179.92% | +67.96% |
| EPS (TTM) | $-1.67 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $9.68M |
| Revenue growth (YoY) | — | +146.73% |
| Net income (latest FY) | $-103.69M | $-250.64M |
| Operating margin | — | -1141.13% |
| Net margin | — | -2588.21% |
| 52-week high | $62.32 | $8.98 |
| 52-week low | $14.79 | $3.04 |
| Distance from 52-week high | -34.24% | -13.03% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +79.77% | +74.78% |
| Average volume | 1.14M | 5.03M |
| Shares outstanding | 73.27M | 358.04M |
| Employees | 67 | 160 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed ELVN by 52.3 percentage points over the past year.
About Enliven Therapeutics
ELVN stock →Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
ELVN vs PGEN FAQ
Which is bigger, Enliven Therapeutics or Precigen?
Enliven Therapeutics (ELVN) is larger, with a market capitalization of $3.00B compared with $2.80B for Precigen (PGEN).
Which stock has performed better over the past year, ELVN or PGEN?
PGEN returned +144.83% over the past 12 months, compared with +92.48% for ELVN (price return, excluding dividends). Past performance does not predict future results.
Are Enliven Therapeutics and Precigen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.